Therefore, inhibition of IDH1 may act as a novel therapeutic approach to alter both the metabolism and epigenetics of HGSC as a pro-senescent therapy.
Introduction
Among all gynecological cancers, epithelial ovarian cancer (EOC) is the most lethal due to dissemination into the peritoneal cavity and omental seeding in late stage disease (1) . High-grade serous carcinoma (HGSC) is the most common histosubtype of EOC and has the worst prognosis (2) . The five-year survival rate for HGSC patients is approximately 47% due to limited screening options and late stage diagnosis (3) . This percentage decreases to 20-35% in women diagnosed with stage III and IV HGSC. Due to their characteristic TP53 mutations, many HGSC patients initially respond to standard-of-care platinum and taxol chemotherapies; however, a significant portion relapse with chemoresistant disease (4, 5) . PARP inhibitors were recently approved as a maintenance therapy for ovarian cancer (6, 7) . Although these inhibitors show promise, especially for homologous recombination-deficient ovarian cancer (8, 9) , some patients do not respond and resistance to these drugs has recently become evident (10, 11) . Therefore, there is an urgent need for novel therapeutic strategies for HGSC patients.
Cellular senescence is a state of stable cell cycle arrest that is induced by multiple stimuli, including shortened telomeres, oncogene activation, DNA damage, and certain therapeutics (12) . Senescent cells are characterized by many hallmarks such as increased β -galactosidase activity (termed senescence-associated β -galactosidase or SA-β-gal), increased repressive histone marks, such as repressive di-and trimethylation marks of histone 3 lysine 9 (H3K9me2/3) at proliferation-promoting genes (termed senescence-associated heterochromatin foci, SAHF), decreased incorporation of the thymine analog bromodeoxyuridine (BrdU), and decreased proliferation (13) (14) (15) .
Due to the decrease in proliferation, therapy-induced senescence is considered a desirable therapeutic outcome (16) (17) (18) . Interestingly, recent evidence suggests that therapy-induced senescence leads to a better 5-year survival rate for HGSC patients (19) .
Tumor cells are characterized by metabolic reprogramming in order to maintain uncontrolled cell proliferation and growth (20) . Tumors specifically reprogram metabolic pathways to allow for the increased need for biomass, such as nucleotides, lipids, and other macromolecules (21, 22) . This metabolic reprogramming is increasingly thought to modulate epigenetic marks, including histone and DNA methylation and histone acetylation (23) . Altered metabolism in cancer cells provides a unique opportunity to exploit these changes as a targeted therapy (20) . Cancer cells undergo anaerobic glycolysis and generate lactate, even in the presence of oxygen (24) , termed the Warburg Effect. Although the Warburg effect is a common feature of many cancers, TCA cycle metabolism remains critical for both ATP production and macromolecule synthesis (25) . Indeed, recent evidence suggests that multiple cancer types have increased TCA cycle metabolism (26) , although less is known about TCA cycle activity in HGSC. Therefore, targeting the TCA cycle in cancer may serve as a novel therapeutic strategy.
Isocitrate dehydrogenase I (IDH1) catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (αKG) in a reversible reaction (27) . IDH1 is well-known for its mutation and the resulting production of the oncometabolite D-2-hydroxyglutarate (D-2HG, aka (R)-2HG) in secondary glioblastoma and acute myeloid leukemia (AML) (28, 29) . However, recent work demonstrates that overexpression of wildtype IDH1 also promotes cancer progression in primary glioblastoma (30) . IDH1 regulates histone marks through production of α KG (30, 31) , which is a co-factor for various histone demethylases (32, 33) . Increased repressive histone methylation is a hallmark of senescence, and histone demethylases have been implicated in altering the epigenome of senescent cells (34) (35) (36) . Therefore, depleting α KG pools by suppressing IDH1 may increase repressive histone methylation to induce senescence. While mutant IDH1 is well-characterized in several cancers (28, 29) , the role of wildtype IDH1 in metabolism and epigenetics has never been investigated in the context of HGSC.
In this study, we determined that HGSC cells preferentially utilize glucose in the TCA cycle. While most TCA cycle enzymes were upregulated in HGSC cells compared to the cell-of-origin fallopian tube (37, 38) , only wildtype IDH1 expression was both increased in HGSC cell lines under spheroid conditions and associated with decreased progression-free survival. Functionally, knockdown of IDH1 induced senescence by increasing repressive histone methylation at two proliferation-promoting gene loci:
PCNA and MCM3. Together, these data indicate that targeting wildtype IDH1 in HGSC represents a novel strategy for this patient population by inducing senescence through epigenetic silencing.
Materials and Methods

Cells and Culture Conditions
Human HGSC Ovcar3, Ovcar10, and Ovcar5 cells lines were cultured in RPMI-1640 medium (Gibco) supplemented with 10% FBS according to ATCC. Human HGSC HeyA8 cell line was cultured in DMEM medium (Corning) supplemented with 10% FBS according to ATCC. The FT282 cell line was a kind gift from Dr. Ronny Drapkin (University of Pennsylvania). PFTE4, FT4-Tag, FT6-Tag, and FT33-Tag were a kind gift from Dr. Anna Loshkin (University of Pittsburgh). Fallopian tube cell lines were cultured in DMEM:F12 supplemented with 2% FBS and 1% penicillin/streptomycin under low oxygen conditions. HEK-293FT cells were used for lentiviral packaging and were cultured in DMEM medium (Corning) supplemented with 10% FBS according to ATCC.
In order to induce spheroid formation, human HGSC Ovcar3 and Ovcar10 cells lines were cultured in 6-well ultra-low attachment (ULA) plates (Corning). Cells were treated with 1mM α KG (Sigma Aldrich) where indicated. All cell lines were cultured in Mycozap and were routinely tested for mycoplasma as described (39) .
Metabolomics
Metabolites were quantified by liquid chromatography-high resolution mass spectrometry after extraction of the cells by 80:20 methanol:water at -80 °C, sonication, centrifugation of protein at 17,000 rcf for 10 mins at 4 °C, evaporation of the supernatant to dryness under N 2 gas and resuspended in 50 µl of 5% 5-sulfosalicylic acid for analysis. Ion pairing reversed phase liquid chromatography-mass spectrometry was conducted by modification of a previously published method on a Ultimate 3000 Binary UHPLC coupled to a Q Exactive HF mass spectrometer (40) . Data were processed in Xcalibur (Thermo). Peak areas were normalized to stable isotope labeled internal standards spiked into each sample before extaction as follows; lactate, pyruvate to 
Lentivirus Infection
Lentivirus was packaged in 293FT cells using the Virapower kit from Invitrogen following the manufacturer's instructions. Cells infected with viruses encoding the puromycinresistance gene were selected with 3μg/ml puromycin.
BrdU Labeling and Immunofluorescence
For BrdU, cells on coverslips were incubated with 1μM BrdU for 30min. Cells were fixed for 10 min at room temperature in 4% paraformaldehyde. After washing the cells three 
SA-β-Gal
SA-β-Gal staining was performed as previously described (41) . Cells were fixed for 5 min at room temperature in 2% formaldehyde/0.2% glutaraldehyde in PBS. After washing the cells twice with PBS, cells were stained at 37°C overnight in a non-CO 2 incubator in staining solution (40 mM Na 2 HPO 4 , 150 mM NaCl, 2 mM MgCl 2, 5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 1 mg/ml X-gal).
Colony Formation Assay
An equal number of cells (5,000 cells/well) were seeded in 6-well plates and cultured for ten days. Cells were then fixed with 1% paraformaldehyde/PBS and stained with 0.05% crystal violet. Wells were destained with 10% acetic acid. Absorbance (590nm) was measured using a spectrophotometer (Spectra Max 190).
qRT-PCR
Total RNA was extracted from cells with Trizol and DNase treated, cleaned and concentrated using Zymo columns (Zymo Research). Optical density values of extracted RNA were measured using NanoDrop One (Thermo Scientific) to confirm an A260 and A280 ratios above 1.9. Relative expression of target genes listed in Table 1 were analyzed using the QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific) with clear 96 well plates (Greiner Bio-One). Primers were designed using the using the delta-delta Ct method.
Chromatin Immunoprecipitation (ChIP)
ChIP was performed as previously described (42) was assessed in triplicate. Enrichment of H3K9me2 was determined by normalizing to a gene desert region (43) . Primer sets used for ChIP-qPCR are detailed in Table 1 .
Western Blotting
Cells lysates were collected in 1X sample buffer (2% SDS, 10% glycerol, 0.01% bromophenol blue, 62.5mM Tris, pH 6.8, 0.1M DTT), boiled to 95°C for 10 min and sonicated. Protein concentration was determined using the Bradford assay. An equal amount of total protein was resolved using SDS-PAGE gels and transferred to nitrocellulose membranes (Fisher Scientific) at 110mA for 2 hours at 4°C. Membranes were blocked with 5% nonfat milk for 1 hour at room temperature. Membranes were incubated overnight at 4°C in primary antibodies in 4% BSA/TBS + 0.025% sodium azide. Membranes were washed 3 times in TBS-T for 5 min at room temperature after which they were incubated with HRP-conjugated secondary antibodies (Cell Signaling, Danvers, MA) for 1 hour at room temperature. After washing 3 times in TBS-T for 5 min at room temperature, proteins were visualized on film after incubation with SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher, Waltham, MA).
Quantification and Statistical Analysis
GraphPad Prism version 7.0 was used to perform statistical analysis. T-test and Oneway ANOVA followed by post hoc Tukey's HSD tests were applied as appropriate.
When indicated, P-values were adjusted according to Benjamini and Hochberg's false discovery rate (FDR). The significance level was established at p < 0.05. Ns= not significant. Heatmaps were generated using the function heatmap.2 from gplots R package v3.0-1. Minkowski distance and ward.D2 method of clustering were used to generate all heatmaps. Kaplan-Meier curves were generated using publicly available ovarian cancer mRNA gene chip data (44) . Ovarian cancer patients were filtered by a serous histosubtype and TP53 mutation to signify HGSC.
Results
Wildtype IDH1 is upregulated in high-grade serous ovarian cancer
To determine whether changes in metabolism correlate with ovarian cancer disease progression, we performed metabolomics on primary fallopian tube (FT) cells and HGSC cell lines. We observed a significant upregulation in the levels of all TCA cycle metabolites (Fig. 1A) . However, we did not observe any consistent changes in glycolytic metabolites in HGSC cells (Fig. S1A) . Indeed, metabolite profiling showed decreased lactate production in HGSC cells compared to FT cells (Fig. S1B) . These data indicate that glucose is preferentially utilized by the TCA cycle in HGSC cells. To determine whether upregulation of enzyme expression is responsible for the observed increase in TCA cycle metabolism, we performed a RT-qPCR analysis of all 27 TCA cycle enzymes in five normal FT cell lines, including two primary and three immortalized lines, and four HGSC cell lines (Fig. 1B) . All HGSC cell lines tested exhibited a significant increase in all TCA cycle enzyme expression except IDH2 when compared to FT cells. Together, these data suggest that TCA cycle metabolism is universally altered in HGSC.
HGSC disseminates to the peritoneal cavity in the form of spheroids during late stage disease (45, 46) . In order to mimic these conditions in vitro, ultra-low attachment (ULA)
plates were used to induce the formation of spheroids. As Ovcar3 and Ovcar10 cells showed a robust increase in TCA cycle metabolites and TCA cycle enzymes (Fig. 1A-B) , we compared TCA cycle enzyme expression in these cells from adherent and spheroid conditions (Fig. 1C) . Under these conditions, only three TCA cycle enzymes showed increased expression: PDK1 (pyruvate dehydrogenase kinase 1), SUCLG2
(succinate-CoA ligase GDP-forming beta subunit), and IDH1 (p<0.001). Further analysis of HGSC patients demonstrated that only high IDH1 expression was associated with a significant decrease in progression-free survival ( Fig. 1D and S1C-D) . Consistently, wildtype IDH1 protein is increased in primary HGSC patient tumors when compared to normal FT tissues (Fig. 1E-F) . Together, these data demonstrate that wildtype IDH1 is significantly upregulated in HGSC compared to FT.
Inhibition and knockdown of wildtype IDH1 inhibits proliferation of HGSC cells
Next, we sought to determine whether upregulation of IDH1 is critical for HGSC proliferation. Therefore, we examined the effects of pharmacological inhibition and knockdown of IDH1 on HGSC cell proliferation. There are currently no commercially available inhibitors of wildtype IDH1; therefore, we used an IDH1 mutant inhibitor (IDH1i) that also targets the wildtype protein at higher concentrations (30, 47) . Under adherent conditions, inhibition of IDH1 in Ovcar3 cells decreased BrdU incorporation and colony formation ( Fig. 2A-D) . Similar results were observed in Ovcar10 cells, indicating this is not a cell line-specific phenomenon (Fig. S2A-D) . We examined genetic knockdown of IDH1 in Ovcar3 cells using two independent hairpins (Fig. 2E) .
Similar to the IDH1 inhibitor, knockdown of IDH1 decreased BrdU incorporation, colony formation, and cyclin A expression (Fig. 2F-J) . Similar results were observed upon IDH1 knockdown in Ovcar10 cells (Fig. S2E-I ). Similar to adherent conditions, proliferation was also decreased upon IDH1 inhibition in spheroid conditions as indicated by decreased cyclin A (Fig. 2K) . Taken together, we conclude that inhibition or knockdown of wildtype IDH1 suppresses proliferation of HGSC cells.
Inhibition and knockdown of IDH1 induces senescence of HGSC cells
Next, we sought to determine the mechanism by which inhibition and knockdown of IDH1 suppresses HGSC cell proliferation. In adherent conditions, knockdown of IDH1 did not induce cell death (Fig S3A) . Interestingly, upon suppression of IDH1, cells exhibited a large and flat morphology, which are characteristic of senescence ( Fig.   S3B ) (48) ; therefore, we investigated whether suppression of proliferation was due to senescence induction. Towards this goal, we examined the expression of senescenceassociated beta galactosidase (SA-β-Gal) activity. Indeed, inhibition of IDH1 increased SA-β-Gal activity when compared to control Ovcar3 cells (Fig. 3A-B) . Other senescent markers such as decreased lamin B1 and increased PML bodies were also observed when IDH1 was inhibited ( Fig. 3C-E) . Similar results were observed in IDH1 knockdown cells ( Fig. 3F-J) . However, the senescence-associated secretory phenotype (SASP) (49) was not robustly increased in IDH1 knockdown cells when compared to etoposide treated cells (Fig. S3C) . Senescence was also observed in Ovcar10 cells upon IDH1 inhibition or knockdown, suggesting this is not a cell line specific effect (Fig. S3D-L) .
Additionally, knockdown or inhibition of IDH1 induced senescence in spheroid conditions as indicated by decreased lamin B1 (Fig. 3K and Fig. S3M ). IDH1 produces α KG in a reversible reaction (50) . Addback of exogenous α KG in IDH1 knockdown partially rescued the senescent phenotype (Fig 3L-O) , suggesting HGSC preferentially utilizes the forward oxidative decarboxylation reaction to produce α KG. These data suggest that inhibition or knockdown of IDH1 induces senescence in both adherent and spheroid conditions and may allow for a sustained anti-tumor response due to a lack of SASP gene expression.
Knockdown of IDH1 induces senescence through increased repressive histone methylation at proliferation-promoting gene loci
Next, we aimed to determine the mechanism by which targeting IDH1 induces senescence. Inhibition of IDH1 has previously been shown to increase reactive oxygen species (51), which is a known inducer of senescence (52) . However, we did not observe an increase in ROS upon IDH1 knockdown (Fig. S4A) , and treatment with the antioxidant N-acetyl cysteine (NAC) did not rescue senescence due to IDH1 knockdown (Fig. S4B) . Moreover, we did not observe an increase in DNA damage, another wellknown mechanism of therapy-induced senescence (Fig. S4C) . Increased repressive histone methylation is observed in senescence. In particular, induction of senescence is due in part to increased histone H3 lysine 9 di-methylation (H3K9me2) at proliferationpromoting gene loci (13, 14, 53) . Increased histone methylation may be due to decreased histone demethylase activity, and αKG, the product of IDH1 activity, acts as a co-factor histone demethylases (31, 32) . Therefore, we investigated whether knockdown of IDH1 modulates repressive histone methylation of proliferation-promoting genes to induce senescence. Chromatin-immunoprecipitation (ChIP) assays using an antibody specific for repressive H3K9 dimethylation (H3K9me2) demonstrated increased H3K9me2 at PCNA and MCM3 gene loci in both Ovcar3 and Ovcar10 cells with IDH1 knockdown compared to controls (Fig. 4A) . Consistently, PCNA and MCM3 mRNA expression was decreased in these cells (Fig. 4B) . Together, these data suggest that knockdown of IDH1 increases histone methylation at proliferation-promoting gene loci to decrease their expression and induce senescence.
Discussion
In this study, we found that the TCA cycle enzyme IDH1 is significantly increased in However, our study demonstrates that FT cells also undergo glycolysis (Fig. S1A-B) ,
suggesting that targeting this pathway may result in toxicity to normal tissue. We found that TCA cycle metabolites are significantly upregulated in HGSC cells compared to FT, which suggests that targeting this pathway may lead to less toxicity. Specifically, we identified wildtype IDH1 as a potential target for HGSC. Recently, the IDH1 inhibitor Tibsovo (ivosidenib, AG-120) was approved for relapsed AML with mutant IDH1 (63).
This inhibitor is also effective against wildtype IDH1, but not wildtype IDH2 (64) . Our data and others suggest that targeting wildtype IDH1 is a rational therapy for multiple cancers (65).
We found that targeting wildtype IDH1 induces a sustained proliferative arrest in HGSC cell lines through induction of senescence. While IDH1 has never been explored in ovarian cancer, this is consistent with previous publications in glioblastoma (30, 66) .
This study found that silencing IDH1 expression in glioblastoma reduces NADPH to induce senescence. NADPH is critical for multiple cellular processes, including nucleotide synthesis and redox homeostasis (67) . Indeed, they found that senescence was rescued by supplementation with both nucleotides and the antioxidant N-acetyl-Lcysteine. Consistently, other groups have shown that reductive carboxylation of IDH1 is increased under anchorage-independent conditions to mitigate reactive oxygen species (ROS) (68) . While these studies linked IDH1 to increased oxidative stress, we did not observe a significant increase in reactive oxygen species in HGSC cells with IDH1
knockdown (Fig S4A-B) . This suggests that there is a context or cell type-dependent regulation of senescence by targeting IDH1.
Late stage HGSC primarily disseminates to the peritoneal cavity in the form of spheroids (69, 70) . These cells then seed on organs within the peritoneal cavity, which in part leads to the morbidity and mortality of late-stage ovarian cancer (1). We found that inhibition and shRNA-mediated knockdown of IDH1 induced senescence in both adherent and spheroid conditions (Fig. 3) . This observation suggests that targeting IDH1 may be a therapeutic strategy for HGSCs at various stages including early and late stage diagnoses. Moreover, HGSCs are universally characterized by p53 mutations (71) (72) (73) and ~20% have decreased RB1 (encoding for retinoblastoma protein, RB) (74).
While these two pathways are implicated in the senescence-associated cell cycle arrest (75, 76) , our data suggest that targeting IDH1 downregulates proliferation promoting genes through epigenetic modifications independent of p53 and RB status.
Senescence is characterized by marked chromatin remodeling and increased repressive histone methylation, collectively termed the senescence-associated heterochromatin foci (SAHF) (13, 14) . Specifically, di-and tri-methylation of histone 3 lysine 9 at the loci of proliferation promoting genes is implicated in senescence. We found that knockdown of IDH1 induced H3K9 methylation at PCNA and MCM3 gene loci (Fig. 4A) , two E2F1-responsive proliferation-promoting genes involved in senescence induction (13) . This led to a decrease in expression of these genes (Fig. 4B) . Previous publications found that mutant IDH1, through the oncometabolite 2-hydroxyglutarate (2HG), alters histone methylation at DNA damage response and differentiation gene loci through competitive inhibition of histone demethylases that require α KG for their activity (77, 78) . Alterations in histone demethylases have been connected to senescence induction (36, 79, 80) . Our data suggest that demethylated H3K9 is critical for ovarian cancer cells to proliferate, and targeting this pathway is a novel therapeutic to inhibit ovarian cancer proliferation via senescence. Future work is needed to determine the specific histone H3K9 demethylase responsible for the senescent phenotype.
Senescence is considered a tumor suppressive mechanism, and senescence induction is considered a beneficial therapeutic outcome (16, 19, 81) . However, senescence may also promote cancer through the senescence-associated secretory phenotype (SASP), which increases inflammation and alters the surrounding microenvironment milieu (82).
We found that SASP gene expression was not increased upon IDH1 knockdown (Fig.   S3C) , suggesting that targeting IDH1 may lead to a sustained cell cycle arrest and therapeutic response. Our results in addition to others suggest that senescence induction in the cell-type specific context of ovarian cancer may overall be tumorsuppressing (17, 19, 83) . Altogether, we propose that targeting IDH1 may act as a novel pro-senescent therapy for HGSC patients.
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N-acetyl-L-cysteine supplementation
Cells were treated with 500 μ M n-acetyl cysteine (NAC Sigma Aldrich) where indicated.
YSI Metabolite Measurement
Lactate production was measured using a YSI 2950 Bioanalyzer (Yellow Springs, OH).
Briefly, the same number of cells were seeded in 12-well plates and media was changed 24-hours later. The next day, fresh media was harvested and cells were counted to normalize for proliferation. 
